Why Young Women's Heart Attacks Are So Often Missed

She was 34. Marathon runner. No family history, no hypertension, cholesterol that any cardiologist would describe as ideal. When she walked into the emergency department that evening, she was describing jaw pain and three weeks of fatigue so heavy she had stopped running entirely. The attending physician documented anxiety and work-related stress. It took a second ECG — ordered almost as an afterthought — to find the STEMI that had been there all along. By the time the catheterization suite was ready, 38% of her left ventricular function was already irretrievably gone.

That case was not unusual. Not even close. In the catheterization laboratory, there is a pattern that repeats itself with a consistency that becomes, after enough years, genuinely difficult to accept. Young women arrive later than they should. Their initial presentations get misread. And somewhere between the triage desk and the intervention suite, a window that could not be reopened quietly closes. Not because of negligence — but because the diagnostic reflex most clinicians carry was built on a patient profile that looks nothing like the woman sitting in front of them. Jujur, this is the observation that stays with you long after the shift ends.

Heart attacks in young women are rising. Not slightly — meaningfully. A landmark analysis in Circulation tracked hospitalizations for acute myocardial infarction among women aged 35 to 54 over 15 years and found a 31% increase. Men in the same bracket? Flat. That divergence does not happen without a reason. And the reason, it turns out, has been sitting in the evidence base for decades — largely unaddressed.

The Diagnostic Framework Was Built on the Wrong Patient

Here is the part that is harder to hear than it should be. The clinical definition of a "classic" heart attack — crushing substernal chest pain radiating to the left arm, diaphoresis, ST-elevation on the first ECG — was derived almost entirely from studies on middle-aged men. Women were systematically excluded from the landmark cardiovascular trials of the 1970s and 1980s. The resulting diagnostic template fits male physiology well. Female physiology? Considerably less so.

And the consequences are not abstract. Young women who suffer myocardial infarctions are significantly less likely to receive timely reperfusion. Less likely to be admitted directly to cardiac care units. And — this is the number that should be in every medical curriculum — 2.3 times more likely to die in hospital than men of the same age with equivalent infarcts. Not because female hearts are weaker. Because the system was not built to recognize what cardiac events look like in them.

What the Symptoms Actually Look Like

Not chest pain. Usually not, anyway. This is the single most important thing to understand — and the single most consistently missed in emergency department triage.

Research across multiple large cohorts shows that 59.3% of women experiencing acute myocardial infarction do not report classic substernal chest pain as their primary symptom. What they report instead: jaw pain that comes and goes over days. A fatigue so heavy and unfamiliar it does not feel like ordinary tiredness — more like the body running on a battery that is almost dead. Nausea. Shoulder ache. Breathlessness during activities that were never difficult before. And sometimes just a vague, persistent sense that something is wrong, without a clear location attached to it.

These symptoms often appear days or weeks before the acute event. Not in one dramatic moment. That is a crucial distinction — because it means the warning exists, and it still gets missed. Or, more accurately, it gets attributed to something else.

The Biology Is Different. Not Deficient.

Men tend to develop obstructive coronary artery disease — significant plaque buildup in the large, visible vessels that a standard coronary angiogram is specifically designed to find. But younger women are more frequently experiencing cardiac events through completely different mechanisms. And those mechanisms are largely invisible to the investigations that catch the male pattern.

MINOCA — Myocardial Infarction with Non-Obstructive Coronary Arteries — affects women at a rate 3.4 times higher than men. The angiogram looks clean. No blockage visible. And yet troponin rises, heart muscle dies, and the patient is sent home without the diagnosis she actually needed. It is not that the investigation was done incorrectly. It is that the right investigation was done for the wrong disease.

Coronary microvascular dysfunction sits in the same blind spot. The problem is in the smallest vessels — capillaries and arterioles — which standard imaging does not capture. Think of a large building where the main electrical supply lines are completely intact, but the internal wiring of every individual room has silently failed. Inspecting the supply lines finds nothing wrong. The rooms still have no power. That is what microvascular disease does to the myocardium.

And then there is SCAD — spontaneous coronary artery dissection. A tear in the coronary artery wall, not atherosclerosis. It accounts for a disproportionately high percentage of cardiac events in women under 50, including during pregnancy and the postpartum period. Standard coronary artery disease risk calculators were not built to predict it. They still largely do not.

Risk Factors Nobody Puts in the Calculator

Autoimmune conditions are dramatically more common in women than men. Rheumatoid arthritis, lupus, antiphospholipid syndrome — all of them elevate cardiovascular risk, significantly, in ways that most standard risk calculators simply ignore. A woman with lupus carries roughly a 9-fold increase in myocardial infarction risk compared to a woman without it. That number does not appear on a Framingham Risk Score.

Pregnancy complications are another category that the system has been slow to take seriously as long-term cardiac risk markers. Pre-eclampsia — affecting approximately 5.8% of pregnancies globally — doubles lifetime cardiovascular risk. Gestational diabetes raises future cardiac event risk by a factor of 1.7. Premature delivery before 37 weeks carries meaningful maternal cardiovascular implications that persist for decades. None of this ends when the pregnancy does. But clinically, it is often treated as if it does.

And psychosocial stress — this is not a soft variable. It is a measurable physiological mechanism that affects women's cardiovascular systems differently than men's. Takotsubo cardiomyopathy, triggered by acute emotional stress and occurring predominantly in postmenopausal women, can present identically to STEMI on ECG. It is real cardiac injury. Full stop. The arrhythmias it causes are real. The mortality risk is real. Dismissing it because the trigger was emotional rather than anatomical is one of the more persistent errors in acute cardiac care.

Progress Is Real. The Pace Is Not.

Something is changing. Slowly — but genuinely.

The 2023 ESC Guidelines dedicated specifically to cardiovascular disease in women was a long time coming. Forty years of systematically incomplete data, compressed into a document that will take another decade to fully reach clinical practice. That is not cynicism. That is the documented timeline for guideline-to-bedside implementation in cardiology: between 7 and 17 years. For acute MI — where minutes determine how much myocardium survives — 17 years is not a bureaucratic inconvenience. It is a clinical failure with a measurable body count.

What actually needs to change is simpler than most institutional responses suggest. It is not primarily about new technology or new drugs. It is about a default assumption. The cardiologist facing a 36-year-old woman describing jaw pain and three weeks of fatigue should be thinking cardiac emergency until proven otherwise — not anxiety pending further workup. That shift in clinical default costs nothing. Requires no new equipment. And would save more lives than most of the trials currently in progress.

The thromboembolic complications and myocardial damage that follow a missed or delayed MI are entirely preventable with timely intervention. The knowledge exists. The tools exist. What consistently lags behind is the willingness to apply them without unconscious filtering by patient sex.

Conclusion: The Textbook Needs Rewriting

Here is what the data makes impossible to avoid: young women have heart attacks. At rising rates. With symptoms that look nothing like what most clinicians were trained to recognize as cardiac. Not because their biology is deficient — but because the diagnostic framework they are being evaluated against was never built for them.

That is a solvable problem. It does not require a new drug or a new device. It requires a different starting assumption and the intellectual honesty to acknowledge that the textbook — in this particular area — was written with the wrong patient in mind. And myocardium, once lost, does not come back. The window to act is narrow. And it is the same window for every patient, regardless of sex.

Sanata Firman Syach

Intervention Cardiology Nurse Specialist

Active Civil Servant · Cath Lab Practitioner · Interventional Cardiology

This article is written based on direct clinical experience in the Cath Lab unit and peer-reviewed medical literature. All content is reviewed in accordance with AHA, ESC, and Indonesian Ministry of Health guidelines.